The clinical and laboratory parameters consistently associated with adverse outcomes include advanced age, comorbidities, elevated levels of inflammatory biomarkers such as interleukin (IL-6) and C-reactive protein (CRP), and profound lymphopenia (4–7). Here, CRP is linked to lymphopenia.